MediWound Ltd (M8W) - Net Assets
Based on the latest financial reports, MediWound Ltd (M8W) has net assets worth €50.16 Million EUR (≈ $58.64 Million USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€94.42 Million ≈ $110.39 Million USD) and total liabilities (€44.27 Million ≈ $51.75 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check M8W cash and liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €50.16 Million |
| % of Total Assets | 53.12% |
| Annual Growth Rate | 18.96% |
| 5-Year Change | 328.4% |
| 10-Year Change | N/A |
| Growth Volatility | 100.05 |
MediWound Ltd - Net Assets Trend (2016–2024)
This chart illustrates how MediWound Ltd's net assets have evolved over time, based on quarterly financial data. Also explore M8W total asset value for the complete picture of this company's asset base.
Annual Net Assets for MediWound Ltd (2016–2024)
The table below shows the annual net assets of MediWound Ltd from 2016 to 2024. For live valuation and market cap data, see M8W stock market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | €31.15 Million ≈ $36.42 Million |
-1.40% |
| 2023-12-31 | €31.59 Million ≈ $36.94 Million |
+189.49% |
| 2022-12-31 | €10.91 Million ≈ $12.76 Million |
+338.19% |
| 2021-12-31 | €-4.58 Million ≈ $-5.36 Million |
-163.01% |
| 2020-12-31 | €7.27 Million ≈ $8.50 Million |
-52.06% |
| 2019-12-31 | €15.17 Million ≈ $17.73 Million |
+69.07% |
| 2018-12-31 | €8.97 Million ≈ $10.49 Million |
-6.74% |
| 2017-12-31 | €9.62 Million ≈ $11.25 Million |
+23.81% |
| 2016-12-31 | €7.77 Million ≈ $9.08 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to MediWound Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 9778600000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | €236.20 Million | 758.19% |
| Total Equity | €31.15 Million | 100.00% |
MediWound Ltd Competitors by Market Cap
The table below lists competitors of MediWound Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
JCY International Bhd
KLSE:5161
|
$184.87 Million |
|
E-World
KO:084680
|
$184.89 Million |
|
Bukaka Teknik Utama Tbk Pt
JK:BUKK
|
$184.89 Million |
|
Banco Hipotecario SA
BA:BHIP
|
$184.93 Million |
|
Cabral Gold Inc
V:CBR
|
$184.81 Million |
|
Turk Prysmian Kablo ve Sistemleri AS
IS:PRKAB
|
$184.77 Million |
|
Paninvest Tbk
JK:PNIN
|
$184.75 Million |
|
PW MEDTECH GROUP DL-0001
F:PWE
|
$184.70 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in MediWound Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 31,595,000 to 31,153,000, a change of -442,000 (-1.4%).
- Net loss of 30,224,000 reduced equity.
- New share issuances of 22,165,000 increased equity.
- Other factors increased equity by 7,617,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €-30.22 Million | -97.02% |
| Share Issuances | €22.16 Million | +71.15% |
| Other Changes | €7.62 Million | +24.45% |
| Total Change | €- | -1.40% |
Book Value vs Market Value Analysis
This analysis compares MediWound Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 4.75x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 38.52x to 4.75x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | €0.36 | €13.70 | x |
| 2018-12-31 | €0.33 | €13.70 | x |
| 2019-12-31 | €0.56 | €13.70 | x |
| 2020-12-31 | €0.27 | €13.70 | x |
| 2021-12-31 | €-0.17 | €13.70 | x |
| 2022-12-31 | €1.51 | €13.70 | x |
| 2023-12-31 | €3.43 | €13.70 | x |
| 2024-12-31 | €2.89 | €13.70 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently MediWound Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -97.02%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -149.46%
- • Asset Turnover: 0.28x
- • Equity Multiplier: 2.36x
- Recent ROE (-97.02%) is above the historical average (-97.41%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2016 | -243.05% | -1212.13% | 0.04x | 4.60x | €-19.66 Million |
| 2017 | -230.24% | -887.38% | 0.06x | 4.59x | €-23.11 Million |
| 2018 | -11.78% | -31.08% | 0.10x | 3.93x | €-1.95 Million |
| 2019 | 32.67% | 15.59% | 0.78x | 2.68x | €3.44 Million |
| 2020 | -126.46% | -42.26% | 0.70x | 4.27x | €-9.92 Million |
| 2021 | 0.00% | -57.03% | 1.20x | 0.00x | €-13.09 Million |
| 2022 | -179.58% | -73.97% | 0.53x | 4.58x | €-20.69 Million |
| 2023 | -21.26% | -35.94% | 0.28x | 2.10x | €-9.88 Million |
| 2024 | -97.02% | -149.46% | 0.28x | 2.36x | €-33.34 Million |
Industry Comparison
This section compares MediWound Ltd's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $698,488,333
- Average return on equity (ROE) among peers: -63.13%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| MediWound Ltd (M8W) | €50.16 Million | -243.05% | 0.88x | $184.83 Million |
| TIZIANA LIFE SCIENCES LTD (0RP) | $5.54 Million | -319.56% | 1.20x | $157.03 Million |
| Theravance Biopharma Inc (0TB) | $441.80 Million | 197.40% | 0.37x | $828.57 Million |
| PreveCeutical Medical Inc (18H) | $-4.10 Million | 0.00% | 0.00x | $3.34 Million |
| Argen-X (1AE) | $538.39 Million | -12.38% | 0.07x | $44.01 Billion |
| WAVE LIFE SCIENCES LTD. (1U5) | $32.50 Million | -376.16% | 5.37x | $1.12 Billion |
| ZAI LAB LTD0000006 (1ZLB) | $1.38 Billion | -51.05% | 0.17x | $2.05 Billion |
| BioNTech SE (22UA) | $493.49 Million | -36.28% | 0.62x | $23.24 Billion |
| Ascletis Pharma Inc (2VJ) | $2.54 Billion | -12.40% | 0.05x | $2.05 Billion |
| ALPHAMAB ONCOLO.DL-000002 (3NK) | $1.56 Billion | -20.91% | 0.36x | $978.26 Million |
| BIOMIND LABS INC. (3XI) | $-247.66K | 0.00% | 0.00x | $3.31 Million |
About MediWound Ltd
MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in the United States and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in patients with deep partial- and full-thickness thermal burns to burn centers an… Read more